At a glance
- Originator Millennium Pharmaceuticals
- Developer Gene Logic
- Class Obesity therapies
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 27 Jul 2004 As part of the agreement with Millennium Pharmaceuticals, Gene Logic will investigate new therapeutic indications for MLN 4760
- 08 Jun 2004 Discontinued - Phase-I for Obesity in United Kingdom (unspecified route)
- 04 Jun 2004 No development reported - Phase-I for Obesity in United Kingdom (unspecified route)